The leading medical journal “Lancet” published a scientific article on the results of the first and second phase of clinical trials of the vaccine, which included the following features of the Russian “Sputnik V” vaccine.
Human adenovirus vectors have been shown to be effective (adenoviruses are medium-sized viruses 90-100 nm, not encased in an outer lipid bilayer, with a ten-sided protein shell containing the double-stranded DNA genome), despite concerns about the Presence of immunity to adenoviruses. The optimal safe dose has been determined, which allows achieving an effective immune response in 100% of people, even in those who have been infected with the adenovirus, which reduces the feasibility of developing vaccines on the basis of unexplored platforms.
Two different adenovirus vectors, serotypes 5 and 26, have been used in two separate vaccines, which allow achieving a more effective immune response (the same vector for two vaccines that stimulate the defense mechanisms of the immune system).
The adenovirus vectors are being used by the world’s leading pharmaceutical companies, among them the CanSino single-carrier vaccine (China), the Ad5 vaccine from Johnson & Johnson (USA), as well as the Ad25 vaccine. And they have “half” of the Russian vaccine.
Sputnik V vaccine does not contain live human adenoviruses, but rather on human adenovirus vectors that are unable to reproduce, and are completely safe for public health.
Among the most prevalent vaccines for the human adenovirus vaccine, what is used by the US armed forces from 1971 until now, and all new recruits are vaccinated in the US Army. The US Food and Drug Administration approved the human adenovirus vaccines in 2011. More than 10 million US military personnel have been vaccinated with these vaccines.
The Lancet practical article includes links to previous studies supporting the safety of vaccines based on human adenoviruses:
More than 250 clinical studies and more than 75 international publications confirm the safety of vaccines and medicines based on this basis.
The use of drugs based on human adenovirus vectors in practice for more than 15 years. Especially in Ebola vaccines, and the cancer drug “Gendicine”, which has been used in China for more than 12 years.
The “Sputnik V” vaccine was included in the first nine vaccines among the vaccines closest to completing clinical trials in the World Health Organization list, and it is the only vaccine that uses different vectors for injection, while the rest of the pioneering vaccines depend on new technologies such as monkey adenovirus or mRNA, or techniques Outdated, ineffective (disabled virus).
Disadvantages of new methods of vaccine development
Other vaccine development platforms, such as monkey adenovirus vectors or mRNA technology, have not been used before in approved vaccines, and long-term studies have not been conducted on the potential effects on the human body, including risks of developing cancer complications and the effect on fertility.
Western media do not reflect this fact in their materials in any way.
On the other hand, vaccines manufacturers that have not yet been verified put their terms with buyers to protect them from any legal liability, in the event of unforeseen dangerous effects, and some of them have already managed to sign supply contracts for billions of dollars, but Russia is not following this approach.
At the same time, Western companies raise slogans and adopt a “security statement” that places “concern for the public health of citizens” as their main goal. But these officials remain silent about the disturbing facts.
AstraZeneca did not resume clinical trials in the United States of America after volunteers were immediately diagnosed with a serious disease, transverse myelitis, and although the probability of encountering such an event is 1 in 20,000 cases, more countries are aware Today it needs to diversify its vaccine portfolio. The balance between proven technologies such as the human adenovirus vector, and yet unexplored methods such as the monkey adenovirus vector, mRNA, is important, as evidenced by a recent commentary on AstraZeneca research.
In the United States of America and Western Europe, the confirmed platform for human adenovirus vectors represents only 15% of the total vaccines purchased, unlike a number of countries in Latin America, the Middle East, and Asia, where the share is 50%.
Commenting on the Russian vaccine, the virologist and academic specialist at the Russian Academy of Sciences, Dr. Felix Arschoff, stated that the complete eradication of the pandemic will be impossible without the vaccine. The “Sputnik V” vaccine, which was developed by the Gamalia Center, does not use the Coronavirus, neither alive nor dead, but rather uses modern biotechnology, on an installed platform, so that it contains part of the virus’s genetic code, without containing the virus itself, which is excluded Infection, but it guarantees the production of the antibodies needed to protect the body, which was confirmed by the results of the tests. The use of two consecutive injections with different mechanisms ensures the delivery of the virus code to the body, which is the unique feature of the Russian vaccine.
As for Dr. Alexander Rumyantsev, an academic at the Russian Academy of Sciences, he says that the mechanism of action of human adenoviruses is well known and has been studied for nearly 70 years, and many experiences have been accumulated in testing them, including in the Ebola vaccine and the Middle East Respiratory Syndrome (MERS).